A recent review of ketamine trials suggests that the drug showed rapid reductions in suicidal and depressive symptoms in some patients. What the report also highlights, however, are key limitations in clinical trials, including small study sizes, challenges with blinding, potential expectancy bias, and limited long-term safety data.

These issues extend beyond ketamine and reflect broader challenges in psychiatric drug research. The important question remains:
Are medication-induced conditions such as akathisia being consistently and clearly assessed in clinical trials?

MISSD calls for greater transparency and accuracy in clinical drug trials, including clearer adverse-event reporting and improved clinician education. Understanding these distinctions is essential to patient safety.